Core Viewpoint - MicroPort Scientific Corporation has reduced its stake in MicroPort NeuroScience (02172) by selling 19 million shares at a price of HKD 10.25 per share, totaling approximately HKD 194.75 million, resulting in a new holding of about 235.9 million shares, representing 40.32% ownership [1] Summary by Category - **Share Reduction**: MicroPort Scientific Corporation sold 19 million shares of MicroPort NeuroScience at HKD 10.25 each, amounting to HKD 194.75 million [1] - **Post-Transaction Holdings**: After the sale, MicroPort Scientific Corporation's remaining shares in MicroPort NeuroScience are approximately 235.9 million, which corresponds to a 40.32% ownership stake [1]

Core Viewpoint - MicroPort Scientific Corporation has reduced its stake in MicroPort Scientific (02172) by selling 19 million shares at a price of HKD 10.25 per share, totaling approximately HKD 194.75 million, resulting in a new holding of about 235.9 million shares, representing 40.32% ownership [1] Summary by Category - **Share Reduction** - MicroPort Scientific Corporation sold 19 million shares of MicroPort Scientific (02172) [1] - The sale price was HKD 10.25 per share, amounting to a total of approximately HKD 194.75 million [1] - **Post-Transaction Holdings** - After the reduction, MicroPort Scientific Corporation's remaining shares are approximately 235.9 million [1] - The ownership percentage after the transaction is 40.32% [1]

Group 1 - MicroPort Scientific Corporation reduced its stake in MicroPort Scientific (02172) by 56 million shares at a price of HKD 10.11 per share, totaling approximately HKD 566 million [1] - After the reduction, the latest shareholding number is 255 million shares, representing a holding percentage of 43.57% [1]

Group 1 - MicroPort Scientific Corporation reduced its stake in MicroPort Scientific (02172) by 56 million shares at a price of HKD 10.11 per share, totaling approximately HKD 566 million [1] - After the reduction, MicroPort Scientific Corporation's latest shareholding stands at 255 million shares, representing a holding percentage of 43.57% [1]

Group 1 - MicroPort Scientific Corporation reduced its stake in MicroPort NeuroScience (02172) by 56 million shares at a price of HKD 10.11 per share, totaling approximately HKD 566 million [1] - After the reduction, MicroPort Scientific Corporation holds 255 million shares, representing a 43.57% ownership stake [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創腦科學有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02172 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總 ...

Core Viewpoint - The recent stock transfer of MicroPort NeuroTech (02172) indicates a significant shift in shareholder structure, while the company's mid-year performance shows a decline in revenue and profit, highlighting potential challenges in its growth trajectory [1]. Group 1: Shareholder Activity - On October 24, MicroPort NeuroTech's shares were transferred from Construction Asia to Guoyuan Securities Brokerage, with a market value of HKD 856 million, representing 12.94% of the total shares [1]. Group 2: Financial Performance - For the mid-year results of 2025, MicroPort NeuroTech reported revenue of approximately HKD 383 million, a year-on-year decrease of 6.2% [1]. - The company's profit attributable to equity shareholders was HKD 92.923 million, reflecting a year-on-year decline of 35.25% [1]. - Earnings per share stood at HKD 0.16 [1]. Group 3: Product and Market Expansion - As of the reporting period, the company had eight products launched internationally, achieving commercialization in 34 overseas countries or regions [1]. - The products cover nine countries that rank among the top ten globally for neuro-interventional procedures [1].

Core Viewpoint - The recent stock transfer of MicroPort NeuroTech (02172) indicates a significant shift in shareholder structure, while the company's mid-year performance shows a decline in revenue and profit, highlighting potential challenges in its growth trajectory [1] Group 1: Shareholder Activity - On October 24, MicroPort NeuroTech's shares were transferred from Construction Asia to Guoyuan Securities Brokerage, with a market value of HKD 856 million, representing 12.94% of the total shares [1] Group 2: Financial Performance - For the mid-year results of 2025, MicroPort NeuroTech reported revenue of approximately HKD 383 million, a year-on-year decrease of 6.2% [1] - The company's profit attributable to equity shareholders was HKD 92.923 million, reflecting a year-on-year decline of 35.25% [1] - Earnings per share stood at HKD 0.16 [1] Group 3: Product and Market Expansion - As of the reporting period, the company had eight products successfully commercialized in 34 overseas countries or regions [1] - The products cover nine countries that rank among the top ten globally for neuro-interventional procedures [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創腦科學有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02172 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額 ...

Core Viewpoint - The article highlights the collective rise of the MicroPort group stocks following the announcement of MicroPort Medical's restructuring of its cardiac rhythm management business, which aims to alleviate pressure related to meeting listing standards [1] Group 1: Stock Performance - MicroPort Medical (00853) increased by 8.47%, reaching HKD 14.21 [1] - HeartLink Medical-B (02160) rose by 4.55%, reaching HKD 1.38 [1] - MicroPort Robotics-B (02252) saw a 4.28% increase, reaching HKD 28.26 [1] - MicroPort Neuroscience (02172) grew by 2.88%, reaching HKD 12.52 [1] Group 2: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with its subsidiary MicroPort HeartLink planning to merge with CRM Cayman [1] - Upon completion of the merger, CRM Cayman will become a wholly-owned subsidiary of MicroPort HeartLink, focusing on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is reported to be USD 680 million [1] Group 3: Ownership and Investment - MicroPort Medical currently holds a 46.12% stake in HeartLink Medical and a 50.13% stake in CRM Cayman [1] - In July 2021, Hillhouse Capital, along with CPE and Springhill, invested USD 300 million in MicroPort's cardiac rhythm management subsidiary, acquiring a 26.3% stake [1] - There is an agreement that if CRM Cayman does not achieve a qualified listing and a market value of at least USD 1.5 billion by July 17, 2025, MicroPort must repurchase all shares at an annualized return of 8% [1]